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ABSTRACT
Background: Glioblastoma (GBM) is the most common malignant central nervous 
system tumor, and MGMT promoter hypermethylation in this tumor has been shown to 
be associated with better prognosis. We evaluated the capacity of radiomics features 
to add complementary information to MGMT status, to improve the ability to predict 
prognosis.
Methods: 159 patients with untreated GBM were included in this study and divided 
into training and independent test sets. 286 radiomics features were extracted from 
the magnetic resonance images acquired prior to any treatments. A least absolute 
shrinkage selection operator (LASSO) selection followed by Kaplan-Meier analysis 
was used to determine the prognostic value of radiomics features to predict overall 
survival (OS). The combination of MGMT status with radiomics was also investigated 
and all results were validated on the independent test set.
Results: LASSO analysis identified 8 out of the 286 radiomic features to be 
relevant which were then used for determining association to OS. One feature (edge 
descriptor) remained significant on the external validation cohort after multiple 
testing (p=0.04) and the combination with MGMT identified a group of patients with 
the best prognosis with a survival probability of 0.61 after 43 months (p=0.0005).
Conclusion: Our results suggest that combining radiomics with MGMT is more 
accurate in stratifying patients into groups of different survival risks when compared 
to with using these predictors in isolation. We identified two subgroups within 
patients who have methylated MGMT: one with a similar survival to unmethylated 
MGMT patients and the other with a significantly longer OS.
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INTRODUCTION
Glioblastoma (GBM) is the most common 
malignant central nervous system tumor (46.6%) and has 
a poor prognosis with only 5.5% (95% CI 5.2%-5.8%) 
survival at 5 years [1]. Imaging plays an important 
role in determining patient diagnosis, prognosis, risk 
assessment, response evaluation and follow up [2]. 
The standard treatment consists of surgical resection 
followed by radiotherapy with concomitant and adjuvant 
chemotherapy (temozolomide) [3]. Recently, several 
molecular biomarkers have been identified to predict 
prognosis and outcomes to therapy as well as to guide 
personalized therapies [4, 5]. The hypermethylation 
of the MGMT promoter (O6-methylguanine–DNA 
methyltransferase), which results in the silencing of this 
DNA repair enzyme, provides key prognostic data and 
has been shown to be associated with better prognosis 
and better response to temozolomide [6, 7]. We studied 
the utility of combining pre-treatment, diagnostic 
magnetic resonance imaging (MRI)-based radiomics 
features with MGMT methylation to further stratify 
patient prognosis.
Previous studies have applied qualitative visual 
feature descriptors assigned by radiologists from MRI scans, 
such as those based on the VASARI (Visually AcesSAble 
Rembrandt Images) criteria, showing that these may predict 
patient outcomes [8, 9]. Recently, radiomics features of MR 
images have been used to extract quantitative measures of 
whole tumor appearance heterogeneity to predict outcomes 
in multiple cancers including GBM [10]. Radiomics 
involves the extraction of quantitative feature descriptors 
of tumor appearance through edges, textures, shape and 
histogram features through automated high-throughput 
computer analysis of medical images and has been applied 
to predict outcomes in several cancers [10–12]. In brain 
cancer, radiomic features have shown feasibility to predict 
outcomes including survival [13–18].
Radiomics when applied to predict underlying 
genotypic features is called radiogenomics [19–22] 
and has been used to non-invasively detect association 
of images with underlying molecular markers such as 
MGMT methylation, IDH1 mutation and 1p/19q co-
deletion [13, 16, 18, 23, 24]. In our study, we evaluated 
whether the combination of the molecular biomarker 
MGMT and image-based tumor heterogeneity computed 
using radiomics analysis would produce more accurate 
overall survival (OS) classification than MGMT alone. 
We focused on the capacity of radiomics to improve the 
effectiveness of MGMT methylation as a biomarker to 
identify patient groups with distinct survivals among the 
patients with or without MGMT methylation. Our aim 
was to build an easy-to-compute and interpretable model 
incorporating the most relevant radiomics features to 
augment the capacity of MGMT methylation as biomarker 
of outcome.
Analysis consisted of several steps including 
relevant features selection followed by a univariate 
analysis to construct models that could potentially be 
incorporated into routine clinical workflows to inform 
patient prognosis and guide treatment decision making. All 
the analyses were performed on a training cohort and then 
validated on an independent validation cohort following 
the protocol described in Figure 1.
RESULTS
Patient characteristics
Median patient age at diagnosis was 61.5 years 
(range, 18-87) and 40% were female. Seventy percent 
of the patients had a KPS score >80%. Among the 121 
patients with known MGMT status, 40% were methylated. 
A large majority of the patients were IDH wild-type 
(n=137). All patient characteristics including details 
specific to training and external validation cohorts are 
summarized in Table 1.
Feature selection
286 MRI-radiomics features (Figure 2D) were used 
in a least absolute shrinkage selection operator (LASSO) 
regression model to reduce the number of features in the 
training cohort to identify the features most relevant to 
outcome. Different bin sizes of MRI intensity were found 
to have a limited impact on feature selection: the model 
using a 128-bin setting selected the same set of features 
as the model using a 32 or 64-bin setting, and there was 
also a large overlap in the set of selected features with 
that of the model using a 16-bin setting (Supplementary 
Table 1).
The model based on a 128-bin setting selected 
8 MRI-radiomic features as relevant to outcome: 1 
feature from fluid attenuation inversion recovery 
(FLAIR) images (intensity histogram feature category: 
interquartile range), 2 features from T1-weighted 
images (T1WI) images (Gray-Level Co-occurrence 
Matrix (GLCM) feature category: cluster prominence 
and difference variance), 2 features from the contrast-
enhanced T1-weighted (T1WICE)(Gabor feature category: 
G
θ=0, f=2
 Skewness and G
θ=0, f=2
 Mean) and 1 feature from 
the T1WICE images (intensity histogram feature category: 
10th percentile), and 2 shape features (sphericity and 
surface-to-volume ratio).
Overall survival analysis in training cohort
MGMT methylation status
MGMT methylation alone was associated with 
improved OS with a median survival of 36.0 months for 
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methylated patients and 16.8 months for unmethylated 
patients (p=0.02) (see Figure 3A).
Radiomic features
Table 2 presents the optimal thresholds for each 
selected feature obtained with Receiver Operating 
Characteristic (ROC) curve analysis. Of the 8 selected 
features, 4 were significantly associated with OS after 
adjusting for multiple comparisons using the Bonferroni 
procedure: 2 shape features (sphericity and surface-
to-volume ratio) and 2 features from T1WICE images 
(G
θ=0, f=2
 Skewness and G
θ=0, f=2
 Mean). Tumors with high 
sphericity (> 0.73) or surface-to-volume ratio < 1.73 
were associated with a longer median survival (36.0 
months) vs. tumors with low sphericity (17.5 months) 
and tumors with large surface-to-volume ratio (15.5 
months), respectively. Patients with the highest edge 
enhancement on T1WICE (i.e., Gθ=0, f=2 Skewness value 
lower than the optimal threshold [−0.49]) had a longer 
median survival (36.0 months) vs. their counterpart (16.3 
months) (Figure 3B). Median survival times are reported 
in Table 2.
Combination of MGMT and Radiomics
The combination of MGMT methylation status 
and the selected G
θ=0, f=2
 Skewness radiomics feature 
identified a subgroup of patients with a better prognosis 
than their counterparts. Patients with MGMT methylation 
and high negative skewness of Gabor edge enhancement 
had a better prognosis (survival probability of 0.61 after 
43 months of observation) compared with other patients 
(survival probability of 0.15 and median survival of 
17.5 months, (95% CI: 13.4, 21.0)) (p=0.0005). On the 
other hand, patients with MGMT methylation and G
θ=0, 
f=2 Skewness > optimal threshold [−0.49]) did not have 
a significantly different prognosis than patients without 
MGMT methylation (p=0.5) (Figure 3C). MGMT 
methylation status combined with the remaining selected 
features (sphericity, surface-to-volume ratio and G
θ=0, 
f=2 Mean) did not identify subgroups of patients with 
significantly different prognosis.
Overall survival in the validation cohort
MGMT methylation status
In the validation cohort, MGMT methylation alone 
remained a significant prognostic factor with a median 
survival of 19.7 months for methylated patients vs. 13.3 
months for unmethylated patients, p=0.01 (Figure 4A).
Radiomic features
Using the optimal thresholds identified in the 
training dataset, only the G
θ=0, f=2
 Skewness feature from 
Figure 1: Workflow of the study divided on four steps. Training cohort: 1) Radiomics feature selection using the Least Absolute 
Shrinkage and Selection Operator (LASSO) regression model and prognosis value of these features for the OS prediction 2) Prognosis 
value of MGMT and combination of MGMT and radiomics features for the OS prediction. Validation cohort: 3) Validation of the prognosis 
value of the selected radiomics features for the OS prediction. 4) Prognosis value of MGMT and the combination of MGMT and radiomics 
features for the OS prediction on the validation cohort.
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T1WICE images remained significantly associated with 
OS after adjusting for multiple comparisons with the 
Bonferroni procedure (Table 2). Similar to the training 
set, patients with highest edge enhancement on T1WICE 
(G
θ=0, f=2
 skewness< optimal threshold [−0.49], p=0.04) had 
a longer median survival of 20.6 months compared with 
12.2 months for the group with low edge enhancement 
(Figure 4B).
Combination of MGMT and G
θ=0, f=2
 skewness
The validation set confirmed the results of the 
training set: those patients who had both MGMT 
Table 1: Patient characteristics and outcome
Training Cohort 
(n=98)
Validation Cohort 
(n=61)
All (n=159)
Age (median [range]) 64y [20–87] 61y [18–80] 61.5y [18–87]
Gender
F 38 (39%) 26 (43%) 64 (40%)
M 60 (61%) 35 (57%) 95 (60%)
KPS (%)
50% 1 (1%) 1 (2%) 2 (1%)
60% 5 (5%) 7 (11%) 12 (7%)
70% 23 (23%) 2 (3%) 25 (16%)
80% 26 (27%) 25 (41%) 51 (32%)
90% 31 (32%) 4 (7%) 35 (22%)
100% 12 (12%) 13 (21%) 25 (16%)
Unknown 0 (0%) 9 (15%) 9 (6%)
MGMT status
Unmethylated 57 (58%) 15 (25%) 73 (46%)
Methylated 29 (30%) 20 (33%) 49 (31%)
Unknown 12 (12%) 26 (42%) 37 (23%)
IDH status
Wild-type 90 (92%) 47 (77%) 137 (86%)
Mutant 5 (5%) 3 (5%) 8 (5%)
Unknown 3 (3%) 11 (18%) 14 (9%)
Extent of resection
Biopsy 0 (0%) 10 (16%) 10 (6%)
Subtotal resection 52 (53%)
Near total resection 16 (16%) 51 (84%) 149 (94%)
Gross total resection 30 (31%)
OS
median [range] 587d [79 - 1324] 478d [6 - 2368] 567d [6 - 2368]
1yr survival probability 71% 63% 68%
2yr survival probability 43% 25% 36%
3yr survival probability 28% 17% 26%
Vital Status
Dead 56 (57%) 45 (74%) 101 (64%)
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methylation and high negative skewness of Gabor edge 
enhancement had a longer median OS of 22.7 months vs. 
patients who did not and who had a median OS of 12.2 
months (p=0.004) (Figure 4C).
DISCUSSION
Our study differed from the typical radiogenomic 
studies which aim to find correlations between 
Figure 2: From the image acquisition to the radiomics features extraction. (A). Acquisition of T1WI, T1WICE and FLAIR 
sequences. (B). Image segmentation using simultaneously the information from the 3 sequences (in red) and reporting this segmentation on 
all sequences. (C). Image post treatments: Gabor filtering and binning. (D). Radiomics feature extraction.
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radiomics features with genotypic expressions [16, 
18, 23, 24]. Instead, we examined the synergistic 
value of adding radiomics to MGMT methylation 
status to predict prognosis. Increasingly, studies have 
employed next generation sequencing to show the 
predictive utility of underlying tumor genotypic and 
transcriptomic profiles for predicting survival [25, 26]. 
Next generation sequencing studies are not readily 
available at all centers, however, and may be limited by 
the available amount of tumor tissue. In contrast, MGMT 
status is widely available via PCR based methods. We 
therefore tested our hypothesis that textural intra-tumor 
heterogeneity, tumor shape and intensity histogram 
features computed from radiomics analysis could be 
used to augment efficacy of predictive biomarkers such 
as MGMT status.
Results from our study showed that Gabor features 
extracted from T1WICE MRI complements the findings 
using qualitative visual measures using the VASARI 
criteria [27]. For instance, the length of the lesion’s 
major axis on FLAIR, the proportion of contrast-
enhanced on T1WICE and ring enhancement assessed 
from T1WICE images have shown to be associated with 
survival [28] and/or MGMT promoter methylation in 
GBM [29].
We developed a model combining radiomics and 
MGMT methylation status to predict OS and showed that 
the combined model predicted survival in an independent 
validation cohort using the median feature values 
extracted from the training cohort. Our study identified 
the skewness of the Gabor filtered edge image (G
θ=0, f=2
 
Skewness) computed from the T1WICE as a significant 
predictor of survival. High negative skewness of Gabor 
edges was associated with longer OS. Gabor edges are 
directional sensitive edge detectors and large negative 
skewness indicates that patients with longer OS exhibited 
a more homogeneous distribution of edges in their tumors 
compared with those with shorter OS (see Supplementary 
Figure 1).
In contrast to prior works using radiomics analysis 
which showed the prognostic value of measures including 
GLCM [30] and GLSZM (Gray-Level Size-Zone Matrix) 
features for OS prediction [31], none of these measures 
were found to be relevant in our study, even if two were 
selected by the LASSO regression model. We believe that 
these features were not selected or not found to have a 
significant prognostic value due to large variations in MR 
images, such as the voxel size or the magnetic strength, 
within our cohort and within the multi-institutional cohort. 
Indeed, it is possible that such effects influenced the value 
of these features more than patients’ prognosis.
Second, tumor segmentation was performed by 
simultaneously including all three sequences in order to 
extract the entire tumor extent including any visible edema 
on the FLAIR sequence. The Gabor edges were better than 
the whole tumor summary measures such as the GLCM 
features to quantify the appearance difference between 
tumor bulk and edema.
The orientation (0 degree) of the Gabor filter that 
was selected by our model may be explained with the 
shape of the tumors that have their longest diameter 
in the back to front orientation, probably because of 
the shape of the brain. In addition, the results for this 
feature were confirmed on the validation cohort using 
the median value found on the training cohort as the 
threshold.
Figure 3: Overall survival curves for (A) Methylation of the MGMT promoter (n=86 patients); (B) Edge enhancement the 
tumor in T1WICE images (skewness of histogram after Gabor filtering with a direction of 0° and a frequency of 2 – patients 
are split according to the optimal cut-off value τ = −0. 49), (n=98 patients); (C) Combination of the methylation status of the MGMT 
promoter and edge enhancement in T1WICE images (skewness of histogram after Gabor filtering with a direction of 0° and a frequency 
of 2, the reported p-value is for the difference in prognosis for the patients with methylation and heterogeneity under the median vs. the 
rest, (n=86 patients).
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The shape features (sphericity and surface-
to-volume ratio) were not found to be significantly 
associated with OS in the validation cohort. This result 
might be explained by the imbalance in cohort size within 
the group after splitting the training set by the optimal 
threshold. Further investigations are needed to evaluate the 
prognostic value of shape descriptors from MRI images 
in GBMs.
However, the selection of eight features among the 
286 investigated features does not mean that these selected 
features are the only relevant features. Indeed, LASSO 
selects and ranks independent features in the order of their 
relevance for the predicting the outcome variable. In other 
words, features that are correlated with the top-ranking 
features are removed, which reduces the false discovery 
due to multi-testing.
Our analysis identified OS-relevant radiomics 
features. However, unlike other studies that have reported 
a significant correlation between MGMT status and 
radiomics features [23, 32], we found no such correlation. 
Because MGMT status and OS are indirectly connected, 
especially for the survival during the first months [7], it is 
possible that features correlated with MGMT status were 
not selected in our model.
The combination of the G
θ=0, f=2
 Skewness radiomic 
feature and MGMT status identified a group of patients 
with a better prognosis in both the training and validation 
cohorts. These patients had methylated MGMT and a 
high negative value of Gabor edge skewness. At the 
opposite, methylated MGMT patients without a high 
value of Gabor edge skewness had OS indistinguishable 
from unmethylated MGMT patients. We believe that the 
Table 2: Overall survival analysis in the training and validation sets. The 8 features selected by the LASSO 
regression model were used in the training set and the 4 significant features in the training set were used in the 
validation set. All p-values were corrected for multi-testing by the Bonferroni procedure.
Testing set Validation set
median survivals (95% LCL; 
65% UCL) (months)
median survivals (95% LCL; 65% 
UCL) (months)
Image 
sequence
Feature 
category
Feature 
name
cut-off 
value
group 1 (≥ 
cut-off)
group 2 
(<cut-off)
p-values† group 
sizes
group 1 
(≥ cut-
off)
group 2 
(< cut-
off)
p-values† group 
sizes
FLAIR Intensity histogram
Interquartile 
range 175.5
21.7 (18.4; 
NA‡)
16.3 (12.1; 
29.0) 0.8 52/46 - - - -
T1WI GLCM Cluster prominence 1.77E+07
25.9 (21.0; 
NA‡)
17.5 (14.6; 
28.3) 0.32 35/63 - - - -
Difference 
variance 253.7
NA‡ (11.6; 
NA‡)
18.7 (16.3; 
25.9) 0.24 22/76 - - - -
T1WICE
Intensity 
histogram
10th 
percentile 29.5
18.2 (15.5; 
22.2)
NA‡ (NA‡; 
NA‡) 0.06 72/26 - - - -
Gabor 
features
G
θ=0, f=2
 
Mean 144.1
29.0 (18.4; 
NA‡)
16.8 (12.1; 
22.2) 0.02 54/44
15.7 
(13.3; 
22.3)
14.1 (6.8; 
NA‡) 1 51/10
G
θ=0, f=2
 
Skewness -0.49
16.3 (12.4; 
21.7)
36.0 (25.9; 
NA‡) 0.02 56/42
12.2 (8.5; 
19.7)
20.6 
(15.7; 
NA‡)
0.04 31/30
NA Shape Sphericity 0.73 36.0 (19.3; NA‡)
17.5 (12.4; 
22.1) 0.007 47/51
16.0 
(13.9; 
22.3)
8.5 (6.8; 
NA‡) 0.8 50/11
Surface 
to volume 
ratio
1.73 15.5 (11.6; 21.0)
36.0 (19.3; 
NA‡) 0.002 34/64
20.6 
(13.3; 
NA‡)
14.7 
(11.7; 
20.8)
1 16/45
†Significance of difference in the OS between the two groups (p-values were corrected for multiple comparisons with 
Bonferroni procedure)
‡NA values appears when the survivorship function does not reach 0.5
95% LCL and 95% UCL are the 95% lower and upper confidence limits around the median survivals
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radiomic feature quantifies the sharpness of the tumor 
boundary on the T1WICE and might reflect the degree of 
tumor infiltration. An interesting extension of this study 
will be to focus on the correlation between altered genes 
or pathways and the measurements of tumor edges.
Our radiomics approach differs from others 
in a few aspects. First, we used automated tumor 
segmentations with machine learning that was then 
edited or approved with minimal user input. Second, 
the tumor segmentations and ultimately the radiomics 
features were calculated from a single segmented 
volume combining T1WI, T1WICE and FLAIR. Such a 
segmented volume in fact includes the edema visible 
on FLAIR images that will be excluded when using 
only T1WI, and T1WICE scans. Inclusion of edema 
components helps the features to quantify the strength 
of tumor edges.
Our study suffers from some limitations. 
First, features were extracted without histogram 
standardization techniques and voxel resampling 
techniques which could have resulted in the decrease 
or the loss of the prognostic value of several features 
[33, 34]; however, this was done because our goal 
was to build models that could be easily used in a 
clinical practice across institutions and which would 
be applicable for new patients without constraints in 
the image acquisition protocol. Second, we employed 
one segmentation for all sequences. Extracting features 
from different segmentations derived from different 
sequences could have potentially resulted in capturing 
different aspects of the tumor microenvironment. We 
plan to pursue such approach especially for correlating 
image-based features to the genomic pathways in the 
future. Third, we investigated only one feature selection 
technique (LASSO) with the dead or alive status of the 
patients as a binomial outcome. This technique allowed 
us to identify features that are of potential interest, but 
it cannot guarantee the best feature selection. However, 
this method was chosen based on the work of Deist et al., 
who reported that random forest and elastic net logistic 
regression yielded higher discriminative performance 
compared with several other machine learning methods 
[35]. Fourth, although our cohort consisted mostly of 
IDH wildtype GBMs, we included a few IDH mutant 
GBMs that represented 5% of our patients and is 
concordant with the reported proportion of this rare 
mutation in primary GBMs [36]. Nevertheless, the 
model that we developed for untreated GBMs was able 
to successfully predict survival regardless of IDH status. 
Supplementary Table 2  provides the repartition of IDH 
mutant patients into the considered groups and no bias 
due to these patients was found.
Our study showed the combined value of radiomics 
with MGMT in predicting OS in patients diagnosed with 
GBM from pre-treatment MRI using cross-validation 
training and independent test sets. Our results highlight 
that radiomics features possibly contain information that 
is not supplied by molecular markers such as MGMT 
methylation alone. Particularly, we identified that the 
methylated MGMT patients can be split into two groups 
with significantly different survival times. Future studies 
will focus on methylated MGMT glioblastoma patients and 
the ability for the radiologist to visually determine analogs 
to the radiomic characteristics that we have identified.
Figure 4: Overall survival curves for a validation cohort (A) Methylation of the MGMT promoter (n=35 patients); (B) 
Edge enhancement in T1WICE images (skewness of histogram after Gabor filtering with a direction of 0° and a frequency 
of 2). Patients are split using the optimal cut-off value of −0.49 obtained from the training cohort (n=61 patients); (C) Combination of 
the methylation status of the MGMT promoter and edge enhancement in T1WICE images (skewness of histogram after Gabor filtering 
with a direction of 0° and a frequency of 2, the reported p-value is for the difference in prognosis for the patients with methylation and 
heterogeneity under the median vs. the rest, (n=35 patients).
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MATERIALS AND METHODS
Patients
A total of 159 patients with untreated GBM and 
pre-treatment MRI scans were retrospectively analyzed 
in our study, from Memorial Sloan Kettering Cancer 
Center (MSK=112) and from The Cancer Imaging 
Archive (TCIA=47). All patients were scanned with 
MRI consisting of T1WI, T1WICE, and FLAIR images. 
Ninety-eight patients from MSK were included in the 
training set for our study; 78 underwent surgery followed 
by concomitant and adjuvant radiochemotherapy (30 
fractions of 6000cGy and temozolomide) according to the 
standard Stupp protocol [3] and the remaining 20 others 
patients were treated with hypofractionated radiation 
(15 fractions of 4150±610cGy), Optune tumor treating 
fields (Novocure, St. Helier, Jersey) and/or bevacizumab 
(Genetech, San Francisco, CA). After determining the 
training cohort for our study, 61 patients (14 MSK + 47 
TCIA) with brain MRIs and unknown treatments (for 
the TCIA) were used to build an independent validation 
cohort. The analyzed outcome was overall survival 
(OS) defined as defined as the time between the date of 
diagnosis and the last follow-up date or the date of event 
(e.g., death). Radiomics analysis was performed in both 
the training and validation cohorts. To determine if the 
combined performance of radiomics and MGMT status 
would better predict prognosis, we used a reduced cohort 
of 121 patients (86 for training and 35 for validation) with 
known MGMT status (see Table 1).
Memorial Sloan Kettering Cancer Center Patients
This retrospective study was approved by the MSK 
institutional review board with a waiver of written informed 
consent. MR images were acquired using Discovery 
MR750w and MR450w scanners (GE Medical Systems, 
Milwaukee, WI) with a standard head or neurovascular 
coil. The image acquisition details for this cohort are 
provided in Supplementary Table 3. All patients underwent 
maximal safe resection as per standard of care. Tumor DNA 
was tested using a polymerase chain reaction (PCR) based 
assay for MGMT promoter hypermethylation in region +28 
to +47 from the translation start site in exon 1.
TCIA Patients
From the GBM patients in the TCIA database 
(n=262), we excluded those patients who (a) were missing 
at least one of the three sequences, (b) had images with 
severe motion artifacts, and (c) were either recurrent 
GBMs or determined to be post-operative MRIs. This 
resulted in a total of 47 patients between 1998 to 2011 
with pre-operative MRIs consisting of T1WI, T1WICE 
and FLAIR images (included patient IDs are in the 
supplementary material). The image acquisition details 
for this cohort are provided in Supplementary Table 1. 
MGMT methylation status of these patients was obtained 
from the TCGA database using the corresponding patient 
IDs. Further details of the analyzed patients from TCIA 
data can be downloaded on the TCIA website: https://wiki.
cancerimagingarchive.net.
Radiomics features extraction
All tumors were segmented using grow-cut 
segmentation combined with active machine learning 
[37]. The segmentations were validated by an experienced 
neuroradiologist with >18 years of experience with MRI 
and brain tumor imaging (R.J.Y) and manually adjusted 
where required prior to radiomics feature extraction 
(Figure 2B).
Tumor segmentation
The algorithm from Veeraraghavan and Miller 2011 
[37] was modified to simultaneously process multiple MR 
image sequences consisting of T1WI, T1WICE and FLAIR 
images. Prior to segmentation, the image sequences 
were co-registered with a rigid registration using our 
in-house implementation using a C++ wrapper function 
implemented around the Insight ToolKit [38].
Next, starting from user-drawn brush strokes to 
identify the tumor and background regions, the algorithm 
generated segmentation of the tumor by automatically 
combining image intensities from three sequences 
consisting of FLAIR, T1w pre and T1w post-contrast 
images. To generate the segmentation, the algorithm 
learned a model of the tumor through brush stroke 
inputs using a support vector machine (SVM) algorithm, 
following which any regions that were difficult to segment 
were automatically identified by the algorithm and 
presented as queries to the user to indicate whether those 
regions corresponded to tumor or background. Upon user 
input in some of those regions, the algorithm automatically 
refined the tumor segmentation.
Radiomic features
Radiomic features were extracted using the CERR 
software [39], which was demonstrated to be compliant 
with the Image Biomarkers Standardization Initiative 
(IBSI) nomenclature [40]. The MR intensities in all 
images were scaled to Q=128 values using:
V x round
Q x V
V V
1 .
1Q
min
max min
( ) ( ) ( )= − −
−
+




With Vmin and Vmax the minimum and maximum 
intensity value in the tumor segmentation (Figure 2C). 
Additionally, Gabor filtering was applied to extract edge 
maps from the images using four orientations (θ=0°, 30°, 
45° and 90°) and with a frequency f of 2 and 2√2 [41]. 
Gabor filtering consists of applying bandpass filtering 
operation to extract edges in the image. The Gabor edges 
are directional sensitive filters and are composed of a 
Gaussian envelope function superimposed on a sinusoidal 
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wave. In two dimensions, Gabor filters can be used to 
determine the edge response along various orientation 
(or angles) and scales (or bandwidths) of the Gaussian 
function. Using four orientations and two bandwidths on 
the three different MRI sequences resulted in twenty-four 
Gabor edge images.
A total of 286 MRI-radiomics texture, shape, edge 
and intensity histogram features were extracted from the 
unscaled, scaled and Gabor edge filtered MRIs from all 
three sequences (Figure 2D). The full list of extracted 
features is provided in the supplementary file. First-
order features consisted of intensity histogram features 
(n=20) computed from the unscaled MRIs. The scaled 
MRI images were used to compute GLCM [42] and 
GLSZM [43]. An offset of one voxel in all directions 
and 26-connexity was used to extract the co-occurrence 
matrices. One matrix was built to describe the entire tumor 
volume using 3D neighbors and one unique matrix for all 
directions (using the same merging method as described 
in the IBSI [40]) , and then used to extract GLCM features 
[42]. Similarly, one GLSZM was produced and then 
used for extracting tumor heterogeneity features [43]. In 
addition, four main histogram metrics (mean, standard 
deviation, skewness and kurtosis) were extracted from the 
Gabor edge maps.
Statistical analysis
Our study was designed in accordance with the 
guidelines proposed by Vallières et al. for responsible 
radiomics research for faster clinical translation [44]: we 
focused particularly 1) to describe precisely the workflow 
from the image acquisition to the feature extraction and 2) 
to design a study with an independent validation and with 
corrections for multiple testing comparison.
All statistical analyses were performed using 
R software (v3.4.3) and the glmnet, roc and survival 
packages. Feature selection was performed implicitly 
using the Least Absolute Shrinkage and Selection 
Operator (LASSO: elastic net logistic regression with 
the mixing parameter equal to 1) [45] regression model 
with the patient’s dead or alive (56% vs 42% of patients) 
status as a binomial response variable and a 10-fold 
cross-validation was used for the tuning parameter (λ). 
Prior to fitting the model, the features were transformed 
to be in the same scale using the standardization method 
integrated in the glmnet package. The features found to be 
relevant by the model were those that were assigned non-
zero weights by the model. Selected features were then 
used to compute their association with OS. Kaplan-Meier 
analysis was used to determine the association between 
the radiomics features and OS by dichotomizing the 
patients using the best threshold (Youden index) obtained 
from ROC curves analysis of the individual features. 
The p-values were corrected for multiple comparisons 
using the Bonferroni method for controlling the false 
discovery rate. Only p-values <0.05 after adjustment for 
multiple comparisons were considered significant. We also 
combined the relevant radiomics features identified using 
the LASSO method with the MGMT molecular biomarker 
to determine whether the combined model produced better 
discrimination between patients by overall survival.
An independent validation set was used to validate 
the results on radiomics and on the combination of 
radiomics with MGMT for OS prediction. In this 
cohort, the previously selected radiomics features were 
dichotomized using the median value reported in the 
discovery set.
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